-
Contrasting appellate tactics show Amazon feels protected by UK ASI against InterDigital’s Munich AILI, but is scared of UPC sua sponte sanctions
Read more: Contrasting appellate tactics show Amazon feels protected by UK ASI against InterDigital’s Munich AILI, but is scared of UPC sua sponte sanctionsThere are two striking differences between Amazon’s UPC and Munich appeals of InterDigital’s anti-interim-license injunctions.
-
BREAKING: Heath Hoglund, who left Via last month, joins Sisvel as Chief IP Officer
Read more: BREAKING: Heath Hoglund, who left Via last month, joins Sisvel as Chief IP OfficerThis is Sisvel’s highest-profile external hire.
-
Tesla should learn from Amazon-InterDigital, take an Avanci 5G license: even if its long-shot UKSC appeal succeeded, it wouldn’t help
Read more: Tesla should learn from Amazon-InterDigital, take an Avanci 5G license: even if its long-shot UKSC appeal succeeded, it wouldn’t helpFor cross-jurisdictional reasons, Tesla should give up on its UK case against Avanci and InterDigital, in which it lost the first two rounds.
-
UPC President denies Amazon motion to stay enforcement of InterDigital’s anti-interim-license injunction; Amazon may already be in breach
Read more: UPC President denies Amazon motion to stay enforcement of InterDigital’s anti-interim-license injunction; Amazon may already be in breachThis does not mean that Amazon’s appeal will necessarily fail, but Amazon could now face contempt proceedings any day.
-
CJEU publishes European Parliament’s suit against European Commission’s decision to withdraw SEP Regulation
Read more: CJEU publishes European Parliament’s suit against European Commission’s decision to withdraw SEP RegulationThe Commission “prematurely” brought the legislative procedure to an end without legitimate grounds supported by cogent evidence and arguments for doing so, the EP has alleged.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
Read more: China’s top court grants Novo Nordisk win over key Ozempic patentChina’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.
-
UPC Mini-Roundup (1 decision): CoA draws line between invalidity contentions against granted patent vs. amendments; double jeopardy did it again
Read more: UPC Mini-Roundup (1 decision): CoA draws line between invalidity contentions against granted patent vs. amendments; double jeopardy did it againThe Unified Patent Court (UPC) has issued only one publicly accessible decision since our December 29, 2025 Roundup, other than a non-newsworthy withdrawal (yet another case in the Access Advance-Transsion context). This roundup is listed among the 2025 as well as 2026 roundups because New Year’s Day fell mid-week. For hearing lists etc., please check…
Follow Us
Latest Articles
- Gallium nitride patent wars: Innoscience, Infineon clash over Munich injunction rulings
- BREAKING: Nokia, Acer sign patent licensing agreement, will determine terms through arbitration
- Nokia, Lenovo sign patent cross-license agreement on amicable basis
- Huawei becomes first SEP owner to announce Wi-Fi 7 patent licensing rates: $0.50 per unit
- With litigation risk solutions under the microscope, PAE steps up Eastern District of Texas campaign asserting patents purchased from Allied Security Trust